Es gab 50 kürzliche Insider-Transaktionen für Cogent Biosciences, Inc. (COGT), darunter 41 Käufe und 9 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $64.89M und die gesamten Insider-Verkäufe auf $139.58M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Ferrante Karen Jean, Fairmount Funds Management Llc, Green John L.. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — COGT
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-04-01 |
Ferrante Karen Jean |
Director |
RSU-Zuteilung |
686 |
$35.24 |
$24.17K |
686 |
| 2026-03-31 |
Fairmount Funds Management Llc |
Director |
Umwandlung (Verkauf) |
28,000 |
- |
- |
39,414 |
| 2026-01-22 |
Fairmount Funds Management Llc |
Director |
Informierter Verkauf |
3,500,000 |
$36.40 |
$127.4M |
5,503,418 |
| 2026-01-01 |
Ferrante Karen Jean |
Director |
RSU-Zuteilung |
643 |
$34.74 |
$22.34K |
643 |
| 2025-12-26 |
Green John L. |
Chief Financial Officer |
Informierter Verkauf |
77,000 |
$38.68 |
$2.98M |
131,834 |
| 2025-12-26 |
Kearns Evan |
Chief Legal Officer |
Informierter Verkauf |
65,000 |
$38.70 |
$2.52M |
109,398 |
| 2025-12-26 |
Sachs Jessica |
Chief Medical Officer |
Informierter Verkauf |
82,642 |
$38.70 |
$3.2M |
133,938 |
| 2025-12-26 |
Robinson John Edward |
Chief Scientific Officer |
Informierter Verkauf |
90,000 |
$38.74 |
$3.49M |
140,002 |
| 2025-12-17 |
Robbins Andrew R |
President and CEO |
RSU-Zuteilung |
185,000 |
- |
- |
185,000 |
| 2025-12-17 |
Green John L. |
Chief Financial Officer |
RSU-Zuteilung |
50,000 |
- |
- |
53,841 |
| 2025-12-17 |
Kearns Evan |
Chief Legal Officer |
RSU-Zuteilung |
40,000 |
- |
- |
40,000 |
| 2025-12-17 |
Sachs Jessica |
Chief Medical Officer |
RSU-Zuteilung |
50,000 |
- |
- |
51,296 |
| 2025-12-17 |
Robinson John Edward |
Chief Scientific Officer |
RSU-Zuteilung |
50,000 |
- |
- |
50,000 |
| 2025-12-17 |
Pinnow Cole |
Chief Commercial Officer |
RSU-Zuteilung |
65,000 |
$39.45 |
$2.56M |
65,000 |
| 2025-10-01 |
Ferrante Karen Jean |
Director |
RSU-Zuteilung |
1,642 |
$14.13 |
$23.2K |
1,642 |
| 2025-07-10 |
Fairmount Funds Management Llc |
Director |
Informierter Kauf |
2,777,777 |
$9.00 |
$25M |
9,003,418 |
| 2025-07-01 |
Ferrante Karen Jean |
Director |
RSU-Zuteilung |
3,314 |
$7.22 |
$23.93K |
3,314 |
| 2025-06-04 |
Morris Arlene |
Director |
RSU-Zuteilung |
44,700 |
$5.64 |
$252.11K |
44,700 |
| 2025-06-04 |
Ferrante Karen Jean |
Director |
RSU-Zuteilung |
44,700 |
$5.64 |
$252.11K |
44,700 |
| 2025-06-04 |
Harwin Peter Evan |
Director |
RSU-Zuteilung |
44,700 |
$5.64 |
$252.11K |
44,700 |
| 2025-06-04 |
Ros Matthew |
Director |
RSU-Zuteilung |
44,700 |
$5.64 |
$252.11K |
44,700 |
| 2025-06-04 |
Shegog Todd |
Director |
RSU-Zuteilung |
44,700 |
$5.64 |
$252.11K |
44,700 |
| 2025-06-04 |
Cain Christopher W. |
Director |
RSU-Zuteilung |
44,700 |
$5.64 |
$252.11K |
44,700 |
| 2025-04-01 |
Ferrante Karen Jean |
Director |
RSU-Zuteilung |
3,788 |
$5.79 |
$21.93K |
3,788 |
| 2025-01-23 |
Robbins Andrew R |
President and CEO |
RSU-Zuteilung |
915,000 |
$8.89 |
$8.13M |
915,000 |
| 2025-01-23 |
Green John L. |
Chief Financial Officer |
RSU-Zuteilung |
270,000 |
$8.89 |
$2.4M |
270,000 |
| 2025-01-23 |
Kearns Evan |
Chief Legal Officer |
RSU-Zuteilung |
230,000 |
$8.89 |
$2.04M |
230,000 |
| 2025-01-23 |
Sachs Jessica |
Chief Medical Officer |
RSU-Zuteilung |
270,000 |
$8.89 |
$2.4M |
270,000 |
| 2025-01-23 |
Robinson John Edward |
Chief Scientific Officer |
RSU-Zuteilung |
270,000 |
$8.89 |
$2.4M |
270,000 |
| 2025-01-23 |
Pinnow Cole |
Chief Commercial Officer |
RSU-Zuteilung |
240,000 |
$8.89 |
$2.13M |
240,000 |
| 2025-01-14 |
Pinnow Cole |
Chief Commercial Officer |
Informierter Kauf |
43,750 |
$7.60 |
$332.41K |
45,848 |
| 2025-01-01 |
Ferrante Karen Jean |
Director |
RSU-Zuteilung |
2,785 |
$7.80 |
$21.72K |
2,785 |
| 2024-10-01 |
Ferrante Karen Jean |
Director |
RSU-Zuteilung |
2,034 |
$10.75 |
$21.87K |
2,034 |
| 2024-07-01 |
Ferrante Karen Jean |
Director |
RSU-Zuteilung |
2,462 |
$8.94 |
$22.01K |
2,462 |
| 2024-06-10 |
Fairmount Funds Management Llc |
Director |
Optionsausübung (Verkauf) |
1,500 |
- |
- |
- |
| 2024-06-05 |
Morris Arlene |
Director |
RSU-Zuteilung |
44,700 |
$8.92 |
$398.72K |
44,700 |
| 2024-06-05 |
Ferrante Karen Jean |
Director |
RSU-Zuteilung |
44,700 |
$8.92 |
$398.72K |
44,700 |
| 2024-06-05 |
Harwin Peter Evan |
Director |
RSU-Zuteilung |
44,700 |
$8.92 |
$398.72K |
44,700 |
| 2024-06-05 |
Ros Matthew |
Director |
RSU-Zuteilung |
44,700 |
$8.92 |
$398.72K |
44,700 |
| 2024-06-05 |
Shegog Todd |
Director |
RSU-Zuteilung |
44,700 |
$8.92 |
$398.72K |
44,700 |
| 2024-06-05 |
Cain Christopher W. |
Director |
RSU-Zuteilung |
44,700 |
$8.92 |
$398.72K |
44,700 |
| 2024-05-25 |
Pinnow Cole |
Chief Commercial Officer |
Veräußerung |
- |
- |
- |
700 |
| 2024-05-25 |
Pinnow Cole |
Chief Commercial Officer |
RSU-Zuteilung |
525,000 |
$8.22 |
$4.32M |
525,000 |
| 2024-04-01 |
Ferrante Karen Jean |
Director |
RSU-Zuteilung |
3,213 |
$6.90 |
$22.17K |
3,213 |
| 2024-03-28 |
Fairmount Funds Management Llc |
Director |
Sonstige (Verkauf) |
11,914 |
- |
- |
- |
| 2024-02-16 |
Fairmount Funds Management Llc |
10 Percent Owner |
RSU-Zuteilung |
1,500 |
- |
- |
1,500 |
| 2024-01-23 |
Robbins Andrew R |
President and CEO |
RSU-Zuteilung |
1,100,000 |
$4.63 |
$5.09M |
1,100,000 |
| 2024-01-23 |
Green John L. |
Chief Financial Officer |
RSU-Zuteilung |
300,000 |
$4.63 |
$1.39M |
300,000 |
| 2024-01-23 |
Kearns Evan |
Chief Legal Officer |
RSU-Zuteilung |
255,000 |
$4.63 |
$1.18M |
255,000 |
| 2024-01-23 |
Sachs Jessica |
Chief Medical Officer |
RSU-Zuteilung |
300,000 |
$4.63 |
$1.39M |
300,000 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
